Date: 2018-03-05
Type of information: Nomination
Compound: vice president
Company: Retrotope (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases - Neurological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On March 5, 2018, Retrophin announced that Casey Logan has joined the company as vice president, corporate development. Mr. Logan will report to chief operating officer Neil McFarlane, and be responsible for leading global corporate and business development efforts.
- Mr. Logan brings 15 years of experience leading business development, strategic planning and operational activities in the biopharmaceutical industry. He joins Retrophin from Tracon Pharmaceuticals, where he had served as chief business officer since February 2013. At Tracon, Mr. Logan led all strategic, business and corporate development efforts, including the company's IPO in January 2015. Before joining Tracon, Mr. Logan held senior corporate development roles at biopharmaceutical companies Bird Rock Bio (formerly RuiYi) and Anadys Pharmaceuticals, before its acquisition by Roche. Prior to these roles, Mr. Logan was a member of the corporate business development group at Eli Lilly. Mr. Logan served as an officer in the U.S. Naval Nuclear Propulsion Program. Mr. Logan received his B.S.E. in chemical engineering from the University of Michigan, and an M.B.A. from the Kellogg School of Management at Northwestern University.
Financial terms:
Latest news:
Is general: Yes
